Category Archives: AZBio News
LIFE in the Fast Lane: How three Arizona biotech companies are setting the pace
Calimmune, Inc., HTG Molecular Diagnostics, Inc., and VisionGate, Inc. are picking up the pace and when they reach the finish line we all win.Continue reading
Dr. Dan Rudmann Joins Flagship Biosciences as VP of Program Development
Flagship Biosciences continues to expand its leadership position in pathology-focused tissue image analysis with the addition of Dr. Dan Rudmann as Vice President of Program Development.Continue reading
SynCardia Files S-1 with expected price range for IPO
SynCardia Systems has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The expected price range given in the filing was $10 to $12 for 2.5 million shares, with an overallotment option for an additional 375,000 shares. At the maximum price, the total offering is valued up to $34.5 million. According to the S-1, the company intends to list on the Nasdaq Global Market under the symbol TAHT. (Source: 24/7 Wall St.)Continue reading
Making LIFE Better: HTG Molecular Diagnostics receives AZBio Fast Lane Honors
In recognition of its contribution to new innovations and tools in the field of molecular diagnostics for the advancement of precision medicine, HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has been named a 2015 AZBio Fast Lane Company by the Arizona Bioindustry Association (AZBio).Continue reading
Research discovery leads to potential diagnostic for assessing breast cancer recurrence
By measuring DNA methylation, TGen researchers might determine which patients are at higher risk for relapse or metastasesContinue reading
Washington Update – Fall Preview
The latest updates from Capitol Hill as provided by BIO and Republic Consulting Group.
Continue reading